Update in Rheumatology: Evidence Published in 2011
Authors: Lindsy J. Forbess, Anne R. Bass
Journal: Annals of Internal Medicine (2012)

Updates17 July 2012Update in Rheumatology: Evidence Published in 2011Lindsy J. Forbess, MD and Anne R. Bass, MDLindsy J. Forbess, MDFrom Hospital for Special Surgery, New York, New York.Search for more papers by this author and Anne R. Bass, MDFrom Hospital for Special Surgery, New York, New York.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-2-201204030-00408 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this update, we summarize 9 articles published in 2011, many of which are likely to change clinical practice. These include a study describing a “treat-to-target” strategy aimed at inducing disease remission in early rheumatoid arthritis (RA) and an article outlining new international definitions of RA remission. We include a phase 2B trial on the use of a Janus kinase (JAK) inhibitor for RA because these agents show great promise and their efficacy expands our understanding of RA pathogenesis. Studies that led to the recent U.S. Food and Drug Administration approval of belimumab for systemic lupus erythematosus and pegloticase for ...References1. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168-78. [PMID: 19714604] CrossrefMedlineGoogle Scholar2. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143-51. [PMID: 19714615] CrossrefMedlineGoogle Scholar3. Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, et al. A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone. Arthritis Rheum. 2011;:. [PMID: 22006202] MedlineGoogle Scholar4. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56. [PMID: 6691361] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hospital for Special Surgery, New York, New York.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-0131.Corresponding Author: Anne R. Bass, MD, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021; e-mail, [email protected]edu.Current Author Addresses: Drs. Forbess and Bass: Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021.Author Contributions: Conception and design: L.J. Forbess, A.R. Bass.Analysis and interpretation of the data: L.J. Forbess, A.R. Bass.Drafting of the article: L.J. Forbess, A.R. Bass.Critical revision of the article for important intellectual content: L.J. Forbess, A.R. Bass.Final approval of the article: L.J. Forbess, A.R. Bass.Provision of study materials or patients: L.J. Forbess, A.R. Bass.Administrative, technical, or logistic support: L.J. Forbess, A.R. Bass.Collection and assembly of data: L.J. Forbess, A.R. Bass.This article was published at www.annals.org on 19 April 2012. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 July 2012Volume 157, Issue 2Page: 114-119KeywordsAllopurinolDisease modifying antirheumatic drugsGoutH1N1MethotrexateRheumatoid arthritisRheumatologyTumor necrosis factorUric acidVaccines ePublished: 17 July 2012 Issue Published: 17 July 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...